Drug Database
NI

nitroglycerin (GoNitro)

✓ Approved

G. Pohl-Boskamp · 小分子 · 小分子

什么是 nitroglycerin?

nitroglycerin 是一种小分子,由G. Pohl-Boskamp研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)、Sublingual (SL)/Oral Transmucosal。

药物档案

商品名GoNitro
公司G. Pohl-Boskamp
药物类别小分子
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal
状态Approved

治疗适应症

nitroglycerin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved

相关研究文献

PubMedBMC medical imaging2026-11-19

Body size-normalized quantitative assessment of coronary lumen volume following sublingual nitroglycerin at CT angiography.

Balaban Ismail I, Alicioglu Banu B

Sublingual nitroglycerin is widely used before coronary computed tomography angiography to induce coronary vasodilation and enhance visualization of distal coronary segments and small side branches. The aim of the study was to assess the effect of sublingual nitroglycerin on whole-vessel coronary lumen volume in coronary computed tomography angiography and to determine whether this response varies after normalization for body size parameters. This single-center retrospective comparative study included patients who underwent coronary computed tomography angiography using a 128-detector computed tomography scanner. Patients were classified according to pre-scan nitroglycerin administration. In the nitroglycerin group, 400 µg of sublingual nitroglycerin was administered 3-5 minutes before image acquisition. Age-matched patients who did not receive nitroglycerin served as controls. Coronary lumen volumes were calculated semi-automatically using dedicated software and normalized to body mass index and body surface area. The number of coronary side branches and intraluminal contrast enhancement in proximal and distal segments were also assessed. A total of 194 patients were included. Compared with controls, the nitroglycerin group demonstrated significantly larger median coronary lumen volumes (left anterior descending artery: 519 vs 429 mm3, right coronary artery: 634 vs 468 mm3, left circumflex artery: 381 vs 249 mm3), together with higher body size-normalized lumen volumes (all p ≤ 0.009). The number of septal, diagonal, and obtuse marginal branches was also significantly higher in the nitroglycerin group (p < 0.001). The proximal-to-distal contrast enhancement ratios of the left anterior descending and left circumflex arteries were significantly lower in the nitroglycerin group (p < 0.001). Sublingual nitroglycerin significantly increases whole-vessel coronary lumen volume on coronary computed tomography angiography. This quantitative volumetric effect persists after body size normalization and may improve coronary visualization in patients with larger body habitus.

PMID 43052801
阅读全文 →
PubMedJournal of central nervous system disease2026-11-18

Sex-Specific Circadian Dysregulation in the Choroid Plexus of a Nitroglycerin Rat Model of Chronic Migraine: An RNA-Seq Analysis.

Woldeamanuel Yohannes Woubishet YW, Xia Chenchen C, Ding Sam S, Fonteh Alfred A et al.

Migraine patients show choroid plexus (CP) changes, impairing the blood-CSF barrier. The CP regulates circadian rhythms, but links between CP circadian genes and migraine are unexplored. This study examined changes in the CP circadian gene transcriptome in a chronic migraine rat model compared with controls to identify migraine-related pathways. Chronic migraine model: Sprague-Dawley rats (3 females, 3 males) received nitroglycerin (NTG) every other day for 9 days; controls (3 females, 3 males) got saline. CP from the 4th ventricle was collected 2 hours after the final injection for RNA-seq. Migraine Behavior: Von Frey hair tests on days 1, 5, and 9, pre- and 2 hours post-NTG/saline injection, assessed basal and NTG-induced pain thresholds. RNA-seq & Analysis: Differentially expressed genes (p < 0.05, fold change > 1) were identified. GO, KEGG, and Reactome enrichment analyses were performed to assess changes in circadian gene expression. The NTG group showed reduced basal and NTG-induced pain thresholds on days 1, 5, and 9. Females had a greater number of upregulated genes (MT2A, SLC7A11); males had upregulated ZBTB16 and S100A8. SLC7A11, SCG2, and GRIA1 showed inverse regulation (up in females, down in males). Circadian gene expression altered: 10 genes upregulated (e.g., SERPINE1, MAPK9, ATF4), 13 downregulated (e.g., PER2, DBP, EZH2). Sex-specific differences: females (FBXL12, GPR157), males (NKX2-1, ATF4, CLOCK). GO/KEGG analyses revealed significant enrichment of circadian rhythm-related pathways, insulin resistance, and inflammatory response processes, with sex-specific differences: females showed enrichment in HIF-1 signaling and hemoglobin-related pathways, while males exhibited enrichment in arachidonic acid and leukotriene production. CP transcriptomics in the rat migraine model revealed sex-specific gene regulation, with females upregulating antioxidant genes (MT2A, SLC7A11) and males upregulating inflammatory factors (ZBTB16, S100A8), alongside circadian disruption (e.g., SERPINE1 upregulated, PER2 downregulated). Pathway analyses indicate enriched circadian rhythms, HIF-1 signaling (females), inflammatory processes (males), lipid metabolism (PPARα), and heme signaling, highlighting sex-specific and circadian targets for migraine therapy.

PMID 43048019
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Glucuronyl Glucosyloleanolate: A Safe and Potent AI-Discovered Depigmenting Saponin.

Quesnel Yannick Y, Gold Michael M

Saponins are amphiphilic glycosides found in plants. They have long been used in traditional Asian remedies for their anti-inflammatory, protective, and rejuvenating properties. One representative, Glucuronyl Glucosyloleanolate (GGO), was recently discovered using a combination of artificial intelligence and experimental testing as a depigmenting agent. Its safety has been verified in humans during a patch test on 12 volunteers, followed by an HRIPT study on 100 volunteers. Finally, its depigmenting efficacy has been demonstrated after a clinical trial on 60 volunteers. A 48-h patch test was conducted on 12 volunteers using the pure compound.HRIPT: a patch with 0.1% GGO in mineral oil was applied to 100 volunteers repeatedly over 3 weeks. After a 2-week rest, a single patch was applied again to the induction site and to a new, untreated site for the challenge phase.Clinical trial: monocentric blind study of GGO (0.01% weight) versus placebo on a multi-ethnic panel with pigmentation spots. Safety: No skin irritation or adverse effects were observed in the patch test assay confirming the product's excellent safety. On the 100 volunteers, during the induction period, no reaction of irritation was observed after 3 weeks and during the challenge phase, no allergic reaction was observed. Based on these results, GGO demonstrated very good skin compatibility and does not show a sensitizing effect.Efficacy: all subgroups showed significant depigmentation from Day 21 onwards, which continued to increase in a similar manner to that observed with localized depigmentation. After 84 days, the level of depigmentation achieved was 10% on Asian, 14% on Caucasian and North African skin, and 24% on black skin. Dark Pigmentation spots on Asian and Caucasian skin depigmented at a rate 34% faster than the overall skin tone, resulting in their visual fading. Glucuronyl Glucosyloleanolate, identified through AI-enhanced biopharma strategies, shows strong skin-brightening efficacy and safety. It depigments dark spots faster than skin tone brightening in an 84-day clinical trial. Non-irritant and potent at low doses, it promises broad cosmetic and medical applications (melasma). Future investigations should assess its anti-aging and antioxidative potential to broaden its scope of application.

PMID 43047176
阅读全文 →
PubMedPsychopharmacology2026-11-18

Psychedelic experience intensity during ketamine treatment and antidepressant outcomes.

Mathai David S DS, Goldy Sean P SP, Hull Thomas D TD, Arden Kristin K et al.

Ketamine is an effective antidepressant, but the role of acute subjective effects in treatment response remains unclear. Prior studies rely largely on dissociation measures focused on adverse events, which may not capture broader effects across multiple phenomenological domains. To evaluate whether subjective psychedelic intensity during ketamine treatment, considered beyond an adverse-event framework, is associated with antidepressant outcomes. In this retrospective longitudinal cohort study, 3,637 adults with moderate-to-severe depression received up to 4 doses of sublingual ketamine over 4 weeks within a telehealth-supported treatment program. Subjective effects were assessed using the Mindbloom Psychedelic Intensity (MPI) scale, a novel 5-item measure capturing emotional, cognitive, physical, visual, and auditory effects. Primary outcomes included end-of-treatment change in Patient Health Questionnaire-9 (PHQ-9) scores, clinically significant change, and treatment response trajectories. Pre-registered analyses evaluated whether MPI scores at the midpoint of treatment were associated with antidepressant outcomes. Higher subjective intensity scores at 2 weeks were associated with greater reductions in depression severity at 4 weeks, increased likelihood of clinically significant change, and greater likelihood of membership in an improvement trajectory, independent of dose and other covariates. Subjective intensity of the ketamine experience was robustly associated with antidepressant outcomes. These findings suggest that subjective drug effects represent a clinically meaningful correlate of treatment response and highlight the importance of assessments designed to capture first-person experiences with ketamine, with implications for future mechanistic research and clinical care.

PMID 43045823
阅读全文 →
PubMedActa biomaterialia2026-11-17

Mucoadhesive carboxymethyl cellulose-pullulan dissolving microneedles for sublingual delivery of peanut allergens in immunotherapy.

Kim Minsoo M, Nam Jeehye J, Park Shinyoung S, Cho Sung Min SM et al.

Peanut allergy remains a major clinical challenge due to the risk of severe anaphylaxis and limitations associated with current immunotherapies, including poor compliance in oral immunotherapy (OIT) and insufficient antigen retention in sublingual immunotherapy (SLIT). In this study, we developed a polysaccharide-based sublingual dissolving microneedle immunotherapy (SDMNIT) platform composed of a mucoadhesive carboxymethyl cellulose-pullulan (CMC-PL) film optimized for sublingual retention, a CMC-PL-hyaluronic acid (HA) base matrix engineered to suppress salivary leakage and improve localized payload confinement, and peanut extract (PE)-loaded HA microneedle tips for efficient allergen deposition into the sublingual mucosa. In vitro characterization demonstrated favorable rheological behavior, controlled dissolution, enhanced mucoadhesion, reduced salivary washout, and efficient sublingual insertion with localized payload retention under simulated oral conditions. In vivo evaluation in peanut-sensitized mice showed that SDMNIT attenuated challenge-induced allergic responses and was associated with reduced histamine and PE-specific immunoglobulin E (IgE) levels and changes in antibody and splenic cytokine profiles. Allergen-specific measurements also demonstrate tissue-associated Ara h 2 after sublingual administration. Overall, these findings support that SDMNIT enables effective localized mucosal immune modulation and dose-sparing allergen delivery under dynamic sublingual conditions, thereby providing a promising platform for the development of advanced allergen-specific immunotherapy approaches for peanut allergy. STATEMENT OF SIGNIFICANCE: Current allergen immunotherapies, including oral immunotherapy (OIT) and sublingual immunotherapy (SLIT), are limited by gastrointestinal (GI) exposure, poor allergen retention, and imprecise mucosal delivery, reducing therapeutic efficacy and patient compliance. This study presents a rationally engineered carbohydrate polymer-based sublingual dissolving microneedle immunotherapy (SDMNIT) platform that integrates complementary biomaterial functions through a mucoadhesive carboxymethyl cellulose (CMC)-pullulan (PL) film, a CMC-PL-hyaluronic acid (HA) base, and peanut extract (PE)-loaded HA microneedles (MNs). Systematic optimization of the multilayer structure improved localized allergen delivery, enhanced immune modulation, and enabled dose-sparing therapeutic efficacy in peanut-sensitized mice. This work demonstrates how biomaterial engineering can improve allergen-specific mucosal immunotherapy and provides a broadly applicable strategy for localized transmucosal drug delivery.

PMID 43044703
阅读全文 →
PubMedLangenbeck's archives of surgery2026-11-17

Towards alpha-blockade-free surgery for pheochromocytoma and paraganglioma: experience from a newly established adrenal center.

Knyazeva P P, Meyer A A, Thal S C SC, Bachmann T T et al.

Pheochromocytomas are rare catecholamine-secreting tumors for which surgical resection is the definitive treatment. Traditionally, preoperative alpha-adrenergic blockade is strictly recommended. However, recent evidence has questioned its necessity. In this study, we report our experience with pheochromocytoma surgery at a newly established adrenal center without prior specialization in adrenal surgery. From May 2022 to May 2026, 18 patients (14 female, 4 male; median age 63.1 years, interquartile range (IQR) 46.2-70.1) with catecholamine-producing tumors (15 pheochromocytomas and 3 paragangliomas) underwent surgical resection in our institution. Seventeen patients did not receive any preoperative alpha-adrenergic blockade, whereas one patient underwent surgery while already receiving phenoxybenzamine therapy initiated by the referral physician prior to admission. Intraoperative management included general anaesthesia, central venous access, and invasive arterial blood pressure monitoring. Urapidil and/or nitroglycerin were used as the primary antihypertensive agents. Data were prospectively collected and retrospectively analyzed, including patient demographics, preoperative metanephrine and normetanephrine secretion, intraoperative treatment of hypertension and hypotension, and postoperative outcomes. The median operative time was 49.5 min (IQR, 30-90). Sixteen procedures were performed minimally invasively (15 retroperitoneoscopic and one laparoscopic), and two by open approach. Partial adrenalectomy was performed in seven cases. Histology confirmed chromaffin cell tumors in all cases, with a median tumor size of 4.0 cm (IQR 3.15-5.15). Median peak intraoperative systolic blood pressure was 195 mmHg (IQR, 166-200). For intraoperative blood pressure control, urapidil was administered to 4 patients (22.2%), nitroglycerin to 3 (16.7%), and both agents to 3 (16.7%). The remaining 8 patients (44.4%), did not require pharmacological treatment. Ten patients (55.6%) had a maximum intraoperative noradrenaline requirement < 0.2 µg/kg/min, 5 (27.8%) required intermediate doses of 0.2-0.4 µg/kg/min, and 3 (16.7%) required high doses > 0.4 µg/kg/min. Median postoperative hospital stay was 2 days (IQR, 2-3). Two patients developed transient atrial fibrillation. No major complications or mortality occurred. Our results support the feasibility of alpha-blockade-free surgery for pheochromocytoma, even in centers with limited prior experience in pheochromocytoma surgery. Education of the anaesthesiology team, structured perioperative protocols, and close interdisciplinary collaboration appear to be important for ensuring safe perioperative management.

PMID 43043502
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nitroglycerin